-
Mindray Partners with Vazyme Biotech to Develop Automated Infection Screening Solutions
•
China-based medical device company Mindray (SHE: 300760) has entered into a partnership with fellow Chinese firm Vazyme Biotech Co., Ltd. (SHA: 688105). The collaboration aims to develop a comprehensive automated solution for infection screening and respiratory pathogen detection. Advancing Diagnostic Capabilities with AutomationThe partnership will leverage the combined expertise of…
-
Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval
•
Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug HS336, intended for the treatment of advanced solid tumors. HS336: A Novel SHP2 Inhibitor for Anti-Tumor TherapyHS336 is a…
-
Hainan Boao Lecheng Introduces 319 Overseas Drugs and Devices, Reports Significant Growth
•
The Hainan Boao Lecheng International Medical Tourism Pilot Zone has introduced 319 clinically urgently needed overseas drugs and medical devices with special licenses since receiving permission in 2018. According to the Hainan Provincial Information Office, the number of approved licensed medical devices increased by 62% year-on-year (YOY) in 2022, and…
-
Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology
•
US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district of Shanghai with an investment of USD 100 million. The new unit is controlled by Moderna Biotech UK, and the legal representative is Christoph Brackmann, Moderna’s vice-president of finance, as reported by a local media…
-
Hubei Leads National Volume-Based Procurement of Patented Traditional Chinese Medicines
•
The Healthcare Security Administration (HSA) bureau of Hubei province has released a notification outlining plans to lead a nationwide allied volume-based procurement (VBP) tender focused on patented traditional Chinese medicines (TCMs). This initiative aims to streamline the procurement process for these essential medicines across participating regions. Procurement Cycle and AgreementsThe…
-
Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals
•
China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib clinical study of its CTLA-4 antibody porustobart (HBM4003) in combination with Junshi Biosciences’ (HKG: 1877, SHA: 688180) PD-1 inhibitor toripalimab for the treatment of hepatocellular carcinoma (HCC) at the American Society of Clinical Oncology (ASCO)…
-
Ascentage Pharma’s Olverembatinib Earns Breakthrough Designation for SDH-Deficient GIST
•
The China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to olverembatinib, a Category 1 drug developed by Suzhou Ascentage Pharma Co., Ltd’s (HKG: 6855) wholly-owned subsidiary, Guangzhou Shunjian Biopharmaceutical Technology Co., Ltd. The designation targets succinate dehydrogenase (SDH) deficient gastrointestinal stromal tumors (GIST) that have received…
-
Abbisko Therapeutics Reports Positive Phase Ib Results for ABSK021 at ASCO
•
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) is poised to announce positive results from a Phase Ib clinical study of its drug ABSK021 (pimicotinib) in the treatment of tenosynovial giant cell tumor (TGCT) at the American Society of Clinical Oncology (ASCO) annual meeting. Impressive Objective Response Rates for PimicotinibThe…
